Follistatin vs Klotho
How Follistatin and Klotho compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Follistatin and Klotho come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Follistatin vs Klotho, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Follistatin | Klotho |
|---|---|---|
| What it is | Endogenous glycoprotein that binds and neutralizes myostatin and activin; sold online as a research peptide, and studied in humans only as gene therapy | Endogenous type I single-pass transmembrane glycoprotein (a large membrane protein, not an injectable peptide) |
| Class / category | GH secretagogues | Longevity / mitochondrial |
| Evidence tier | Animal-only · Helped · none in humans | Human observational · Unclear |
| Studied / approved for | Muscle growth / myostatin inhibition; Muscular dystrophy (gene therapy); Age-related muscle loss (sarcopenia) | Safety and health outcomes after plasmid KL gene delivery in healthy adults; Safety and alpha-klotho expression after AKL003 mRNA delivery in adults |
| US regulatory status (2026) | research use only (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 14 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Unknown |
| Key risks | Human safety data for the injectable follistatin peptide are essentially absent. What little human safety information exists comes from small gene-therapy trials, where the localized approach was generally tolerated over the study window — which is not the same as establishing that an injected follistatin peptide is safe. Follistatin sits in pathways that also touch reproduction, inflammation and cell growth, so blocking them broadly is not consequence-free, and no long-term human data exist. | No completed human trial has established the safety of raising alpha-klotho through plasmid or mRNA delivery, and no long-term safety data exist for healthy people. The registered studies are designed to collect tolerability and laboratory safety data, so adverse-event frequencies are not yet known. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Klotho
Klotho's evidence sits at human observational, a more human tier than Follistatin's animal-only. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Follistatin — indexed research (PubMed, National Library of Medicine)
- 2.Follistatin gene transfer in Duchenne muscular dystrophy (ClinicalTrials.gov NCT02354781)
- 3.Follistatin gene transfer in Becker MD and inclusion-body myositis (ClinicalTrials.gov NCT01519349)
- 4.Injectable follistatin plasmid gene therapy, Phase 1 (ClinicalTrials.gov NCT06411366)
- 5.FDA — approved-drug database (no approved follistatin product)
- 6.WADA / USADA Prohibited List — myostatin-function modifiers (S4)